Streetbeat News

Revenues

CTRN

Citi Trends, Inc. (NASDAQ:CTRN) shares are trading lower after reporting mixed Q1 results and revising its FY24 outlook. The company reported a 3.7% increase in quarterly sales to $186.3 million, missing Wall Street's estimate of $187.37 million. Despite a narrower adjusted EBITDA loss and better-than-expected adjusted loss per share, the company lowered its FY24 comparable store sales outlook. CTRN shares are down 3.65% premarket.

Portfolio Pulse from Nabaparna Bhattacharya

June 04, 2024 | 12:15 pm

WMT

Walmart Data Ventures has launched Digital Landscapes, a new platform designed to provide detailed customer data to suppliers. This initiative aims to enhance supplier relationships and improve business outcomes by leveraging Walmart's extensive customer data.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 12:14 pm

BMY

Bristol Myers Squibb presented data from the Phase 3 CheckMate -9DW trial, showing that the combination of Opdivo and Yervoy improved overall survival in patients with advanced hepatocellular carcinoma compared to Lenvatinib or Sorafenib.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 12:14 pm

SOBR

SOBR Safe shares are trading higher following the announcement that two new customers have purchased the SOBRsure device.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 12:10 pm

MOBX

Mobix Labs Inc. (NASDAQ:MOBX) has been selected to supply high-performance connectors for the U.S. Navy's Standard Missile-6 program and has completed its initial product delivery. This marks a significant milestone for the company in the defense sector.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 12:05 pm

BA

Turkish Airlines is reportedly close to finalizing a deal with Boeing for up to 250 aircraft, including 737 Max jets and 787 Dreamliners. This deal could be significant for Boeing as it works to rebuild its reputation following quality control issues.

Portfolio Pulse from Benzinga Neuro

June 04, 2024 | 12:05 pm

MGRX

Mangoceuticals, Inc. (NASDAQ:MGRX) has introduced a new pharmaceutical product named 'MOJO,' which is a compounded formula featuring Enclomiphene Citrate and Pregnenolone for treating low testosterone and male hormone imbalances. The product will be sold exclusively on MangoRx's website on a subscription basis for $199 per month.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 12:01 pm

LSCC

Analysts have provided mixed ratings for Lattice Semiconductor (NASDAQ:LSCC) over the past quarter, with a majority being bullish. The average 12-month price target has increased to $81.78, up from $77.44. Despite a recent revenue decline, the company shows strong net margins and low debt levels.

Portfolio Pulse from Benzinga Insights

June 04, 2024 | 12:01 pm

LEGN

Legend Biotech (NASDAQ:LEGN) has been analyzed by 18 analysts over the past three months, showing a range of perspectives from bullish to bearish. The average 12-month price target has increased to $81.61, up 3.74% from the previous $78.67. Analysts have maintained mostly 'Buy' and 'Outperform' ratings, with some adjustments in price targets. Legend Biotech has shown strong revenue growth but faces challenges in ROE and ROA.

Portfolio Pulse from Benzinga Insights

June 04, 2024 | 12:00 pm

BARK

BARK shares are trading lower after the company reported worse-than-expected Q4 financial results and issued Q1 and FY25 revenue guidance below estimates.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 11:56 am